Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 5/20 | 0.39 |
| ▸ | PDE8A | O60658 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601425 | 1.00 | P2RX7 (0.48) | P2RX7LMNATP53YTHDC1PDE8A | |
| SCHEMBL3441186 | 0.84 | CDK1 (0.54) | PDE8A | |
| SCHEMBL28444699 | 0.84 | YTHDC1 (0.38) | P2RX7YTHDC1HDAC4HDAC1HDAC6 | |
| SCHEMBL28442794 | 0.84 | HSP90AB1 (0.52) | HDAC4HDAC1HDAC6HSP90AA1HSP90AB1 | |
| SCHEMBL28454215 | 0.79 | FDPS (0.51) | P2RX7LMNAHDAC6 | |
| SCHEMBL29444616 | 0.78 | CDK1 (0.51) | P2RX7LMNATP53YTHDC1HDAC4 | |
| SCHEMBL183244 | 0.78 | CDK1 (0.51) | P2RX7LMNATP53YTHDC1HDAC4 | |
| SCHEMBL21268677 | 0.78 | SLC29A1 (0.42) | HSP90AA1HSP90AB1ADORA2B | |
| SCHEMBL29388400 | 0.78 | SLC29A1 (0.42) | HSP90AA1HSP90AB1ADORA2B | |
| SCHEMBL22912741 | 0.76 | SLC29A1 (0.36) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097262-A1 | CHEMOPROTEOMIC CAPTURE OF RNA BINDING ACTIVITY IN LIVING CELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-05-10 | — | — | WO | claimed |
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-11 | — | — | US | claimed |
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | claimed |
| WO-2021016263-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-01-28 | — | — | WO | claimed |
| WO-2024097262-A1 | CHEMOPROTEOMIC CAPTURE OF RNA BINDING ACTIVITY IN LIVING CELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021016263-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021016263-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-01-28 | — | — | WO | disclosed |
| CN-108358927-B | 1, 4-disubstituted 1,2, 3-triazole nucleoside analogue, and preparation method and application thereof | 郑州大学 | 2020-09-01 | — | — | CN | disclosed |
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1456209-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | DDB1, HSPBP1, ATIC | P2RX7 1162/4885LMNA 3475/4885TP53 538/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | P2RX7 61/4885LMNA 2965/4885TP53 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.